BD expects to bring the system to market in early 2026.
BD (NYSE: BDX) announced today that the FDA granted 510(k) clearance for its EnCore EnCompass breast biopsy and tissue removal system.
SALT LAKE CITY--(BUSINESS WIRE)--3M Health Information Systems is expanding its market-leading 3M 360 Encompass System platform to introduce 3M 360 Encompass System – Professional, the industry’s ...
Becton, Dickinson and CompanyBDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its ...
SALT LAKE CITY--(BUSINESS WIRE)-- Healthcare reform, new compliance regulations, and the move to outcomes-based payment are putting pressure on clinical documentation and coding processes at hospitals ...
(RTTNews) - Becton, Dickinson and Co. (BDX) today announced that the U.S. FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, a next-generation device ...
The 3M™ 360 Encompass™ System seamlessly integrates CAC, CDI, concurrent quality metrics, and analytics to capture, analyze, and advance patient information across the continuum of care SANTA CLARA, ...
BOSTON--(BUSINESS WIRE)--TransPerfect Medical Device Solutions and 121nexus today announced an update to the EnCompass system for content automation and distribution. The updated system is designed to ...